Five Year Summary

All figures are in US$ million unless stated otherwise	2021-22 Constant Currency(1)	2021-22 Reported(2)	2020-21 Reported	2019-20 Reported	2018-19 Reported	2017-18 Reported
Total Operating Revenue	10,668	10,562	10,310	9,151	8,539	7,915
Sales Revenue	10,243	10,136	9,980	8,797	8,205	7,588
R&D Investment	1,173	1,156	1,001	922	832	702
Profit before Income Tax Expense	2,711	2,780	2,963	2,573	2,341	2,281
Net profit after tax	2,236	2,255	2,375	2,103	1,919	1,729
Net cash inflow from Operating Activities		2,629	3,622	2,448	1,644	1,902
Capital investment		1,636	1,667	1,367	1,285	992
Return on Invested Capital (%)		18.1	21.2	21.6	24.3	25.9
Basic earnings per share ($)		4.81	5.221	4.633	4.236	3.822
Dividend per share ($)		2.22	2.22	2.02	1.850	1.720

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL's Financial Statements for the Full Year ended 2022 (Directors' Report).
(2) The Group's reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).

Track our recent performance by year, region and major product group.

All figures are in US$ million unless stated otherwise	2019-20 Constant Currency(1)	2019-20 Reported(2)	2018-19 Reported	2017-18 Reported	2016-17 Reported	2015-16 Reported
Total Operating Revenue	9,295	9,151	8,539	7,915	6,947	6,115
Sales Revenue	8,938	8,797	8,205	7,588	6,616	5,909
R&D Investment	933	922	832	702	667	614
Profit before Income Tax Expense	2,741	2,573	2,341	2,281	1,690	1,556
Net profit after tax	2,247	2,103	1,919	1,729	1,337	1,242
Net cash inflow from Operating Activities		2,448	1,644	1,902	1,247	1,179
Capital investment		1,344	1,285	992	861	566
Return on Invested Capital (%)		21.6	24.3	25.9	24.5	26.8⁽³⁾
Basic earnings per share ($)		4.633	4.236	3.822	2.937	2.689
Dividend per share ($)		2.02	1.850	1.720	1.360	1.26

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL's Financial Statements for the Full Year ended 2019 (Directors' Report).
(2) The Group's reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis' global influenza vaccine business of US$176.1 million.

2019/20 Annual Report

CSL reported net profit after tax was US$2,103 million for year ended 30 June 2020. On a constant currency basis, net profit after tax was US$2,247 million. Total ordinary dividends for the year were US$2.02 per share.

This browser is no longer supported

Five Year Summary

Track our recent performance by year, region and major product group.

2019/20 Annual Report

Introduction to CSL

Board and Management

Corporate Governance